INTRODUCTION
Before 2010, the standard therapy for most patients with advanced melanoma was chemotherapy, which had low response rates and minimal impact on survival. 1 In 2002, activating missense mutations in the BRAF gene were identified in 40% to 60% of melanomas. 2 These BRAF mutations result in constitutive activation of the BRAF kinase protein and thus promote hyperactivation of the mitogen-activated protein kinase (MAPK) signaling pathway, an essential regulator of cell proliferation and survival (Fig. 1) . 3 Targeting aberrant MAPK signaling via the selective inhibition of mutant BRAF as well as the downstream protein mitogen-activated protein kinase kinase (MEK) has shown significant antitumor activity in melanoma patients with BRAF-mutant melanoma. [4] [5] [6] In addition to BRAF, several other genes are commonly mutated in melanoma (Fig. 1) , and these may also provide novel therapeutic opportunities. The NRAS gene is mutated in 10% to 30% of cutaneous melanomas, and this leads to a constitutively active NRAS protein capable of stimulating the MAPK and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathways. 7 Activation of the P13K/AKT pathway can also be triggered by a loss of phosphatase and tensin homolog (PTEN) function in melanomas. PTEN loss via gene mutation or deletion has been identified in 10% of melanomas and results in unchecked activation of the P13K/AKT signaling pathway. 7 Neurofibromin 1 (NF1), a negative regulator of RAS, is also mutated in 12% of all melanomas, 8 and mutations in this gene can lead to RAS and, therefore, MAPK activation. 9 Recent studies of melanomas using next-generation sequencing have identified additional recurrent mutations affecting genes involved in MAPK and PI3K/AKT signaling (mitogen-activated protein kinase kinase 1 8, 10 (reviewed by the Cancer Genome Atlas Network 10 and Zhang et al 11 ). This complex genetic landscape highlights the core signaling pathways that regulate melanoma proliferation, growth, and survival and helps to define new therapeutic targets.
Targeting the MAPK and PI3K/AKT signaling pathways in melanoma with selective inhibitors has produced remarkable antitumor activity. However, the development of resistance to these targeted therapies remains a major barrier to complete tumor eradication. In this review, we describe the molecularly targeted therapies that selectively inhibit oncogenes and oncogenic signaling pathways in melanoma with a specific focus on BRAF and MEK inhibitors. We further detail the mechanisms underlying drug resistance and discuss strategies for improving the response durability and circumventing the resistance associated with selective inhibitors in melanoma.
TARGETING DRIVER MUTATIONS AND SIGNALING PATHWAYS IN MELANOMAS
Melanoma harbors many genetic alterations, but the inhibition of a single oncogene is often sufficient to induce tumor regression. This concept of oncogene addiction (ie, dependence on a dominant driver oncogene) relies on the fact that recurrent mutations activating oncogenes (eg, BRAF and NRAS) have a significant impact on survival and proliferation signaling pathways such as the MAPK and/or PI3K/AKT pathways. 12 Although oncogene addiction has been demonstrated in melanoma, it is important to recognize that less frequently occurring alterations, acquired at various stages of tumor evolution, may also promote tumor fitness and therapy resistance.
The inhibition of the mutated BRAF protein with selective kinase inhibitors has been the greatest breakthrough in targeted therapy to date. Several inhibitors of other oncogenes have shown efficacy in preclinical models, and most have progressed to clinical trials (Table 1) , but success has been variable.
Inhibition of Mutant BRAF With BRAF Inhibitors
Approximately 40% to 50% of cutaneous melanomas harbor activating mutations in the BRAF gene, and 80% to 90% of these mutations result in a single amino acid substitution of valine for glutamic acid at codon 600 (BRAF   V600E   ) . 22, 23 Although less common, the substitution of valine for lysine (V600K; 15%), arginine (V600R; 3%), or aspartic acid (V600D; 3%) also occurs in melanoma, and all these substitutions result in increased BRAF kinase activity and hyperactivation of MAPK signaling. 24 Several kinase inhibitors have been developed that selectively target the V600-mutated form of BRAF. Both vemurafenib and dabrafenib bind the active site of the BRAF kinase and are more specific for inhibiting the BRAF V600 -mutant protein versus wild-type BRAF or CRAF. [25] [26] [27] Inhibition of BRAF with vemurafenib or dabrafenib in BRAF V600 -mutant melanoma cell lines caused potent cell cycle arrest, decreased proliferation, and increased apoptosis. 28, 29 Furthermore, the administration of these selective BRAF inhibitors in mice bearing BRAF V600E -mutant xenograft tumors resulted in remarkable tumor growth delay. 25, 29 Encorafenib (LGX818) is a recently developed new-generation BRAF inhibitor that also targets the BRAF V600 mutation in melanoma. In vitro, encorafenib inhibited MAPK activation and consequent cell proliferation in BRAF V600E melanomas.
30 Figure 1 . Recurrent mutations in melanoma affecting the MAPK and PI3K/AKT signaling pathways. The binding of a ligand to RTKs induces RAS activation and consequent stimulation of 1) the MAPK pathway via activation of the RAF kinases (ARAF, BRAF, and CRAF), MEK1/2 kinases, and ERK kinases and 2) the PI3K/AKT pathway via activation of the PI3Ks, AKT kinases, and the mTOR kinase. MAPK and PI3K/ AKT pathway activation leads to the phosphorylation and transcription of genes involved in cell growth, survival, and proliferation. NRAS, BRAF, NF1, and PTEN are commonly mutated in melanoma, and their mutation frequencies are indicated. AKT indicates protein kinase B; ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase kinase; MEK, mitogen-activated protein kinase kinase; mTOR, mammalian target of rapamycin; NF1, neurofibromin 1; PI3K, phosphatidylinositol 3-kinase; PTEN, phosphatase and tensin homolog; RTK, receptor tyrosine kinase.
Compared with traditional cytotoxic chemotherapy, BRAF inhibitors have higher response rates and lead to significantly improved overall survival. The treatment of patients with BRAF V600 -mutant advanced melanoma with single-agent vemurafenib 31, 32 or dabrafenib 14 produced response rates of 48% to 50% with a median progression-free survival time of 5.1 to 5.3 months and a median overall survival time of 13.6 months. BRAF-mutant melanoma patients treated with encorafenib showed response rates of approximately 70% with a median progression-free survival time of 11.3 months. 15 Although the toxicity is mild, paradoxical activation of the MAPK pathway occurs in wildtype BRAF cells under single-agent BRAF inhibitor therapy, and this results in hyperproliferative skin toxicity and, rarely, the propagation of other RAS-mutant cancers. 33 Moreover, although almost all patients have some initial tumor regression and a rapid improvement in symptoms, the majority develop resistance within the first year of therapy, so long-term disease control is rare beyond 2 years. 
MEK Inhibition for NRAS-and BRAF-Mutant Melanoma
NRAS mutations, present in 10% to 30% of melanomas, 34 are mutually exclusive of BRAF mutations, and this suggests that an alteration in either gene is sufficient to deregulate common downstream effector pathways such as MAPK. 3, 35 However, mutations in NRAS can also trigger activation of the PI3K/AKT and other survival signaling pathways, and this is possibly one of the reasons that NRAS-mutant melanomas appear more aggressive with a worse prognosis than other molecular subtypes. 34, 36 Targeting mutant NRAS may have the added benefit of inhibiting multiple survival pathways, but there is currently no effective means of inhibiting mutant NRAS directly. Previous attempts to inhibit NRAS function have focused on preventing an NRAS association with guanosine triphosphate or NRAS posttranslational modification (farnesylation), but guanosine triphosphate antagonists and farnesylate inhibitors have low specificity and low antitumor activity. 37 The current strategy for treating melanomas with NRAS mutations involves inhibiting the MAPK pathway downstream of RAS because these tumors often rely on MAPK signaling for growth and survival. 38 Because mutant NRAS activates both BRAF and CRAF proteins, the most effective means of perturbing MAPK signaling involve pan-RAF inhibitors or targeting MEK kinases downstream of the RAF proteins. However, it should be noted that pan-RAF inhibitors such as sorafenib have little efficacy in melanoma and little effect on MAPK pathway inhibition, likely because of low selectivity and an inability to dose at a level sufficient to inhibit RAF activity in tumors. 16 Patients with unresectable stage III/IV melanoma were treated with selumetinib (100 mg twice daily) or temozolomide. The median PFS times (78 vs 80 d) were similar in the 2 groups. 17 Patients with advanced wild-type BRAF melanoma were treated with selumetinib (75 mg twice daily) or docetaxel. The median PFS times (4.2 vs 3.9 mo) were similar in the 2 groups. 18 Patients with BRAF V600 -mutant melanoma were stratified by pAKT expression and treated with selumetinib (75 mg twice daily). The median OS (8 vs 18 mo) and the median PFS (2.2 vs 7.1 mo) were higher in the low-pAKT group versus the high-pAKT group. 19 
Trametinib (GSK1120212)
In a phase 3 clinical trial, patients with metastatic BRAF V600 -mutant melanoma received either trametinib (2 mg daily) or dacarbazine or paclitaxel. The median PFS (4.8 vs 1.5 mo) and the OS rate (81% vs 61%) were higher in the trametinib group versus the chemotherapy group. 20 
Binimetinib (MEK162)
In a phase 2 clinical trial, patients with NRAS-or BRAF-mutant melanoma were treated with binimetinib (45 or 60 mg twice daily); 20% of the patients with an NRAS mutation and 20% of the patients with a BRAF mutation showed a partial response.
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Abbreviations: MEK, mitogen-activated protein kinase kinase; OS, overall survival; pAKT, phosphorylated protein kinase B; PFS, progression-free survival.
MEK inhibitors, including trametinib, binimetinib, and cobimetinib, are selective noncompetitive inhibitors of the MEK1 and MEK2 kinases that can inhibit MAPK signaling. In vitro, trametinib induced cell cycle arrest and apoptosis in NRAS-mutant cells with variable potency and with less activity than it did in BRAF-mutant melanomas. Similarly, although trametinib inhibited the growth of mice bearing NRAS-mutant xenografts, trametinib was a more potent inhibitor of BRAF-mutant melanoma xenografts. 36, 39 Trametinib monotherapy in patients with metastatic BRAF V600 -mutant melanoma produced a response rate of 22% and an improved overall survival rate in comparison with standard chemotherapy. 6 Binimetinib showed comparable clinical activity: 20% of the patients with NRAS mutations demonstrated a partial response, and the response rate was similar for patients with BRAF mutations. Compared with standard chemotherapy, binimetinib significantly prolonged median progression-free survival (2.8 vs 1.5 months 21 ). Cobimetinib was administered as a monotherapy to patients with advanced solid tumors in a phase 1 clinical trial and produced partial responses in BRAF V600E -mutant melanoma patients. 40 Although the activity of MEK inhibitors in BRAF-and NRAS-mutant melanomas is modest compared to BRAF inhibitors, such that they are not useful as monotherapy, combinations have been explored, as discussed later.
PI3K/AKT Inhibition
The PI3K/AKT pathway is initiated by ligand-dependent activation of receptor tyrosine kinases (RTKs), which instigate the translocation and activation of AKT and downstream signaling, which includes mammalian target of rapamycin (mTOR) activation. Constitutive activation of the PI3K/AKT pathway has been reported in melanomas as a result of elevated expression of RTK ligands (ie, insulin-like growth factor 1 and epidermal growth factor) or mutations in RTK genes (epidermal growth factor receptor and KIT), PI3K genes (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit a [PIK3CA], phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit b [PIK3CB], and phosphoinositide-3-kinase regulatory subunit 1 [PIK3R1]), and AKT genes (reviewed by Davies 41 ). Loss-of-function mutations in PTEN, which inhibits AKT activation, occur in 10% of melanomas and are associated with increased AKT signaling. 42 Many PI3K/AKT inhibitors have been developed with variable efficacy at suppressing pathway activation in human cancer. These include pan-PI3K inhibitors, isoform-specific inhibitors of PI3K, and inhibitors of AKT. The PI3Ks are divided into 3 subclasses according to their structure and substrate specificity. Class 1 PI3Ks exist as heterodimers of the p110 catalytic and p85 regulatory subunits (PI3Ka, PI3Kb, and PI3Kc) or the p110 catalytic and p101 regulatory subunits (PI3Kd). 43 Isoform-specific PI3K inhibitors target PI3Ka, PI3Kb, PI3Kc, or PI3Kd, and although isoform-specific inhibitors may offer reduced toxicity, their activity may also be limited to tumors dependent on specific PI3K complexes. In contrast, pan-PI3K inhibitors target all 4 PI3K isoforms and may produce better activity, especially in cancers with multiple molecular mutations. 44 Interestingly, clinical data suggest that pan-PI3K inhibitors preferentially inhibit and are more effective in cancers with PIK3CA mutations in comparison with those with PTEN loss. 45 In contrast, early clinical trials using AKT inhibitors reported that tumors showing PTEN loss are more susceptible than PIK3CA-mutated melanomas, although AKT inhibitors also suppressed the growth of tumors with a PIK3CA mutation. 46 However, despite the antiproliferative effects of AKT inhibitors, they produce only marginal antitumor activity in vivo, 47 and this suggests that they do not fully inhibit the AKT pathway or, more likely, that other molecular pathways compensate for AKT inhibition. As such, new therapeutic strategies, including cytotoxic chemotherapy, additional molecularly targeted therapies, and immune checkpoint inhibitors, are needed to enhance tumor control.
Copanlisib, a pan-PI3K inhibitor with preferential activity against the PI3Ka and PI3Kd isoforms, induced apoptosis and cell cycle arrest in melanoma cells with constitutively activated AKT both in cultures and in xenograft mouse models. 48 Buparlisib, another pan-PI3K inhibitor, was recently shown to cause apoptosis in melanoma cell lines and retard metastatic melanoma growth in the brains of mice. 49 A phase 2 clinical trial is currently underway to test the efficacy of buparlisib in patients with melanoma metastatic to the brain (NCT02452294).
RESISTANCE TO MAPK PATHWAY TARGETING IN BRAF-MUTANT MELANOMA
Resistance to therapy may be intrinsic (ie, patients do not respond to therapy from the outset) or may be acquired (ie, patients initially respond to therapy but then progress). Although intrinsic resistance to BRAF inhibitors is rare and occurs in less than 10% of patients with BRAF V600E -mutant melanoma, 50 acquired resistance is nearly universal, and most patients develop resistance within the first year of treatment. 51, 52 Resistance to single-agent MEK inhibitors has also been documented in clinical trials; approximately 70% of patients with metastatic BRAF-mutant melanomas had disease progression within a year of starting trametinib monotherapy. 51 Importantly, more than 80% of patients for whom BRAF inhibitor therapy fails also fail to respond to MEK inhibition, and this suggests the existence of BRAF and MEK cross-resistance mechanisms 53 or the rapid emergence of additional resistance mechanisms upon the switch from BRAF inhibitors to MEK inhibitors.
Tumor cells use numerous mechanisms to resist therapies inhibiting MAPK pathway activity. These resistance mechanisms appear to be heterogeneous between patients, show intrapatient and intratumor heterogeneity, [54] [55] [56] and commonly promote the activity of alternate survival signaling pathways. To demonstrate resistance heterogeneity, a comprehensive examination of clinical and genetic data from 100 patients who had progressed on BRAF inhibitor monotherapy showed that more than 95% of patients with multiple progression biopsies had distinct intertumor and intratumor resistance mechanisms. The study also revealed that MAPK pathway reactivation was common because of NRAS or KRAS mutations, BRAF splice variants, BRAF amplification, and MEK1/2 mutations. Resistant mechanisms independent of MAPK reactivation were also observed but accounted for only 11% of all identifiable mechanisms. 57 It is also worth noting that 25% to 40% of patients have unidentified mechanisms of resistance. 56 Resistance is also common for single-agent inhibitors targeting the PI3K/AKT pathway. Despite harboring PIK3CA mutations, more than 60% of patients with breast and gynecological cancers treated with a PI3K/ AKT inhibitor did not respond to treatment, 58, 59 and more than 60% of the 57 patients with advanced solid tumors (2 of 57 patients presented with melanoma) treated with a PI3K/mTOR inhibitor also showed progressive disease. 60 The failure of these molecularly targeted therapies in achieving long-term responses suggests 1) the existence of escape mechanisms that circumvent oncogene addiction and confer resistance to these targeted therapies, 2) that certain mutations such as alterations activating PIK3CA may not be the principal drivers of tumor survival, or 3) that the therapy may not adequately suppress pathway activity.
Innate and acquired resistance to MAPK inhibition is well understood in the approximately two-thirds of patients who have an identifiable molecular aberration, and the following section details the multiple mechanisms of known resistance to BRAF or MEK inhibitor monotherapy in BRAF-mutant melanoma. 
MAPK Reactivation
MAPK reactivation occurs in 70% to 80% of melanomas that have progressed on BRAF inhibitor monotherapy. 54, 56 MAPK reactivation occurs through multiple mechanisms but is predominantly due to NRAS, BRAF, and MEK1 alterations (Fig. 2) .
BRAF-specific alterations
Mutant BRAF allele amplification occurs in 8% to 30% of patients with BRAF inhibitor resistance. 56 ,61 BRAF amplification promotes MAPK hypersignaling, which can be abrogated by increased concentrations of a BRAF inhibitor. 61 Similarly, colorectal cancer cells bearing a BRAF V600E mutation and resistant to BRAF inhibitors showed BRAF amplification, which induced increased MEK phosphorylation to overcome MAPK inhibition. 62 Several BRAF splice variants have also been associated with BRAF inhibitor resistance 56, 61, 63 (Fig. 3) ; these gene variants lack the RAS binding domain and have an increased tendency to homodimerize. Consequently, BRAF splice variants have diminished affinity for BRAF inhibitors and can trigger downstream extracellular signal-regulated kinase (ERK) activation even in the presence of BRAF or MEK inhibitors. 64 Dimerization of the RAF proteins may have additional implications for MAPK activation, especially in the presence of a RAS mutation. Indeed, BRAF inhibition in wild-type BRAF melanomas induces the paradoxical activation of MAPK signaling, 63 an effect attributed to RAS-independent dimerization of RAF kinases. Treatment of wild-type BRAF melanomas with BRAF inhibitors stimulated dimer complexes of BRAF-CRAF, BRAF-ARAF, and CRAF-CRAF, 65 and the formation of the BRAF-CRAF complexes has been shown to transactivate CRAF and lead to MAPK reactivation. 66 Increased MAPK signaling in wildtype BRAF melanomas treated with BRAF inhibitors may also involve the repression of BRAF autophosphorylation at the phosphate-binding loop. This phosphorylation event maintains BRAF in an inhibitory state and is relieved upon BRAF inhibitor binding to promote BRAF and MAPK activity. 67 Although the use of BRAF inhibitors in wild-type BRAF melanomas is not effective and may appear to have unexpected cancer-promoting effects via MAPK reactivation, it is important to point out that this may pertain only to tumors harboring NRAS mutations and relies on the interaction between the BRAF and CRAF proteins. 68 Melanoma cells with NRAS mutations can induce CRAF to activate downstream MAPK signaling, 69 and in the presence of BRAF inhibition, NRAS-mutant cells further augment CRAF activity. Hence, concomitant targeting of CRAF may be necessary for optimal antitumor activity with BRAF inhibitors in both BRAF-mutant and wildtype melanomas. 68 
Overexpression of alternate MAPKs
In addition to BRAF, overexpression of other RAF proteins has been demonstrated to contribute to BRAF inhibitor resistance. Cancer cells are able to use any of the 3 RAF isoforms to activate MAPK signaling and, as such, may be able to divert from reliance on mutant BRAF. Indeed, BRAF V600E melanoma cells resistant to BRAF inhibitor monotherapy showed elevated CRAF and/or ARAF expression, 70, 71 and this suggests that these cells can switch RAF isoforms to reactivate MAPK signaling.
Overexpression of cancer Osaka thyroid (COT), a kinase identified through DNA library screening of BRAF V600E -mutant cell lines, also conferred resistance to the BRAF inhibitor vemurafenib. COT overexpression promoted MAPK activation through MEK and ERK independently of BRAF. Indeed, elevated COT expression has been identified in melanoma tissues from patients who have progressed on BRAF inhibitor therapy. 72 
Mutations activating MAPK signaling
Mutational activation of the RAS guanosine triphosphatase (GTPase) can undermine both BRAF and MEK inhibition. De novo activating NRAS mutations (Q61K/R/ H, G13R, and A146T) have been identified in 30% of BRAF-mutant melanomas with acquired resistance to BRAF inhibitors. 54, 56, 57 Many of these mutations promote NRAS nucleotide binding and diminish its intrinsic GTPase activity to induce MAPK signaling via CRAF activation. 73 Mutations in RAC1, a RAS GTPase, have been identified in approximately 9% of melanomas, 74 and although the impact of RAC1-activating mutations on BRAF inhibitor sensitivity remains unclear, 75 the RAC P29S mutation has been suggested to confer intrinsic resistance to the MAPK inhibitors vemurafenib and dabrafenib in one report 76 and to promote immunosuppression via programmed death ligand 1 (PD-L1) upregulation in a separate study. 77 Mutations activating MEK1 and MEK2 in a RAFindependent manner occur in approximately 7% of BRAF inhibitor-resistant melanomas. 57 The relative contribution of these mutations to BRAF inhibitor resistance appears to reflect their intrinsic kinase activity and may be context-dependent. For instance, MEK1 mutations in C121S, E203K, Q56P, and K57E show high intrinsic RAF-independent kinase activity and are associated with acquired resistance to BRAF inhibitor monotherapy. In contrast, MEK1 P124L/S/Q mutations, which occur in 8% of untreated BRAF V600 -mutant melanomas, 10 have moderate RAF-independent kinase activity and do not prevent responses to BRAF inhibition, but the rates of response are lower than those with MEK1-wild-type, BRAF V600 -mutant melanoma. 78 Recently, loss-of-function mutations and decreased expression of stromal antigen 2 (STAG2) were identified in tumor samples from melanoma patients with BRAF inhibitor resistance. Loss of STAG2 inhibited the expression of dual-specificity phosphatase 6 (DUSP6), a dualspecificity protein phosphatase that negatively regulates ERK2, and this led to reactivation of the MAPK pathway. 79 
Alternate Signaling Pathways
In addition to MAPK reactivation, compensatory activation of other RTK-mediated and oncogenic signaling pathways can contribute to BRAF inhibitor resistance.
Using a library of 17 pathways commonly implicated in malignancy, Martz et al 80 identified the activation of key survival pathways that conferred resistance to 13 different targeted therapies. Notably, activation of the Notch1 pathway was associated with the acquisition of resistance to MAPK inhibitors in BRAF V600E -mutant melanomas. Increased Notch signaling was shown to stimulate dedifferentiation of melanoma cells and increase cell migration without reactivation of the MAPK or PI3K pathway.
PI3K reactivation is implicated in resistance to BRAF and MEK inhibitors in almost 20% of melanoma patients. 54, 57 Melanoma cells resistant to BRAF inhibition showed enhanced insulin-like growth factor 1 receptor/PI3K signaling, and significant tumor cell death was achieved only with cotargeting of this pathway with MEK inhibitors. 71 In addition, patients with BRAF-mutant melanomas treated with MEK inhibitors showed tumor regression but only in a cohort with low AKT activity, whereas no significant response was observed in patients with high AKT activity; this suggests that the inhibition of MEK may induce alternate signaling compensation in the AKT pathway. 19 Likewise, inhibition of MEK has been shown to paradoxically induce AKT signaling to promote tumor survival in BRAF-mutant melanoma cells. 81 Using a mouse model of melanoma coupled with Sleeping Beauty transposon mutagenesis, Perna et al 82 identified several candidate genes involved in BRAF inhibitor resistance. In particular, ERAS was shown to confer resistance by inducing hyperphosphorylation of AKT via inactivation of the proapoptotic protein BAD.
Many growth and differentiation factors bind and activate RTKs, and RTK activation is implicated in monotherapy resistance. Enhanced expression of plateletderived growth factor receptor b (PDGFRß) was observed in a subset of melanoma cell lines and patient biopsies treated with the BRAF inhibitor vemurafenib. Because no evidence of MAPK reactivation was detected, one proposed mechanism involved activation of alternate survival signaling pathways mediated by PDGFRß. 73 An analysis of melanoma tumors also showed upregulated epidermal growth factor receptor expression in more than 30% of BRAF-and MEK-resistant tumors. 83 In addition to melanoma cells, stromal cells can also contribute to resistance via RTK-mediated signaling. For example, Straussman et al 84 demonstrated that stromal cells secrete hepatocyte growth factor, which can activate the hepatocyte growth factor receptor MET on melanoma cells and thus lead to reactivation of the MAPK and PI3K pathways.
CURRENT APPROACHES TO OVERCOMING RESISTANCE TO TARGETED THERAPY FOR BRAF-MUTANT MELANOMA
The response of BRAF-mutant melanoma to BRAF or MEK single-agent monotherapy is disappointingly shortlived, and almost all patients ultimately progress on treatment. Although ongoing treatment beyond progression may have a clinical benefit in select patients, 85 clearly the goal is to delay or prevent resistance in the first place.
Das Thakur et al 86 showed that intermittent BRAF inhibitor treatment, rather than continual drug dosing, was more effective in mice bearing vemurafenib-resistant melanomas. Discontinuation of the BRAF inhibitor led to the regression of BRAF-amplified resistant tumors, presumably via oncogene-induced senescence, a potent tumor-suppressive mechanism driven by oncogenic stimulation. On the basis of these findings, it has been postulated that an intermittent dosing strategy may prevent the emergence of drug resistance and additionally maintain tumor control. 87 The benefit of an intermittent dosing schedule of dabrafenib and trametinib for progressionfree survival in BRAF-mutant melanoma patients is currently being investigated in a phase 2 clinical trial (NCT02196181).
Aside from alternative dosing strategies, current approaches to preventing or delaying resistance have focused on combination therapies in the hope that affecting more than one oncogene and/or pathway can offer more durable and prolonged responses. Melanoma cells harboring BRAF V600E mutations display increased sensitivity to MEK inhibition in comparison with cell lines with wildtype BRAF or mutant RAS. Enhanced sensitivity was attributed to downregulation of cyclin D1 expression and increased cell cycle arrest, 39 and these findings support the combination of BRAF and MEK inhibitors to enhance antitumor efficacy. Several combination therapies have now been established in preclinical models and in clinical trials.
Combination of BRAF and MEK Inhibitors
Combination BRAF and MEK inhibition delayed the emergence of resistance to a single-agent BRAF inhibitor, in part by blocking MAPK reactivation in melanoma cells. 88 In a subset of melanoma cell lines, prolonged treatment of cells with vemurafenib led to reactivation and recovery of ERK signaling and thus rendered the cells insensitive to BRAF inhibition. However, the addition of a MEK inhibitor in combination with vemurafenib delayed resistance and significantly inhibited melanoma growth and survival. 89 The concomitant administration of BRAF and MEK inhibitors has also been shown to abrogate paradoxical BRAF inhibitor-induced MAPK signaling and reduce the occurrences of proliferative skin lesions; this suggests that secondary malignancies should also be less frequent. 20, [90] [91] [92] Combinations of the BRAF inhibitors and MEK inhibitors were tested in several phase 3 clinical trials in which the combination treatments were compared with treatment with a BRAF inhibitor alone. 91, 93, 94 Findings from these trials confirmed that combination treatment (dabrafenib/trametinib and vemurafenib/cobimetinib) had higher response rates (approximately 65%-70%), improved progression-free survival (median, approximately 12 months), and improved overall survival (median, approximately 24 months) with less cutaneous toxicity, 20, 90 and such combinations are now the standard-of-care targeted therapy for patients with BRAF V600 -mutant melanoma.
Combination of PI3K/AKT Inhibitors and MAPK Inhibitors
The sensitivity of BRAF-mutant melanoma cells to BRAF or MEK inhibitors can be enhanced through combined inhibition of the PI3K/AKT pathway. 95 The inhibition of both mutant BRAF kinase and the PI3K/AKT pathway has synergistic effects in inducing apoptosis in BRAFmutant melanoma cell lines. 96 Similarly, combined targeting of MEK and PI3K was more effective than targeting either pathway in NRAS-mutant melanoma cells; inhibition of MEK and PI3K abolished tumor growth in NRAS-mutant melanoma cells and caused regression in NRAS-mutant tumor xenografts in mice. 97 In uveal melanomas harboring activating Q209L/P mutations in GNAQ or G protein subunit a 11 (GNA11), a combination of the MEK inhibitor GSK1120212 and the pan-PI3K inhibitor GSK2126458 induced significant tumor cell apoptosis in comparison with the inhibition of either pathway alone. 98 Aside from upfront combination therapy with MAPK inhibitors, the addition of PI3K/AKT inhibitors may overcome BRAF or MEK inhibitor resistance. Screening of melanoma cells resistant to vemurafenib has indicated that the majority of these cells are also resistant to the MEK inhibitor selumetinib. As such, the treatment of resistant melanoma cells with vemurafenib and selumetinib did not decrease the phosphorylation of the AKT and MAPK downstream target S6, and this suggests that increased AKT pathway activity may contribute to resistance. In support of this, the combination of vemurafenib or selumetinib with an AKT inhibitor reversed the resistance of melanoma cells to vemurafenib. 99 Similarly, melanoma cells resistant to dabrafenib also showed reduced sensitivity to the MEK inhibitor trametinib, and the addition of the PI3K inhibitor GSK2118136 to either dabrafenib or trametinib treatment abrogated resistance; this resulted in significant tumor growth inhibition. 88 Enhanced antitumor activity with combination treatment was also reported in vivo; mice bearing trametinibresistant tumors were treated with a combination of dabrafenib and trametinib or with a combination of dabrafenib, trametinib, and the PI3K inhibitor GSK2126458. Mice that received the triple combination showed decreased tumor growth, and this suggests that better tumor growth inhibition can be achieved by simultaneous targeting of the MAPK and PI3K pathways. 100 Strategies to disrupt aberrant PI3K/AKT signaling include targeting the downstream effector mTOR. Melanoma cells resistant to vemurafenib showed upregulation of PDGFRß, ERK, and AKT signaling, and the simultaneous inhibition of BRAF, PI3K, and mTOR suppressed melanoma cell growth but was ineffective at inducing cell death. However, a combination of PI3K and mTOR inhibitors with a MEK inhibitor induced apoptosis. 101 In keeping with this, BRAF-mutant melanomas resistant to treatment with BRAF or MEK inhibitors showed persistent mammalian target of rapamycin complex 1 activity, and suppression of mTOR activity induced melanoma cell death. 102 Despite the promising preclinical data, the clinical combination of PI3K/AKT inhibitors with BRAF or MEK inhibitors has been disappointing. A phase 1 trial (NCT01476137) testing the safety and tolerability of trametinib in combination with the AKT inhibitor afuresertib showed only a partial response in a patient with wildtype BRAF melanoma. 103 Several clinical trials are currently ongoing; they include a combination of the PI3K inhibitor buparlisib with BRAF inhibitors or MEK inhibitors in solid cancers (NCT01155453) and a combination of the PI3K inhibitor copanlisib with a MEK inhibitor in melanoma (NCT01392521). However, because of the early-phase (phase 1) nature of these trials, it is not possible to determine conclusively the efficacy of these combinations until phase 2 and 3 trials with larger patient cohorts have been initiated.
Combination of BRAF/MEK Inhibitors With Immunotherapy
Immune checkpoint inhibitors targeting the cytotoxic T lymphocyte antigen 4 (CTLA-4) and the programmed death 1 (PD-1) receptors (ie, ipilimumab, pembrolizumab, and nivolumab) have generated significant durable responses and prolonged survival in melanoma patients. Accumulating laboratory and translational data in support of the antitumor activity and largely nonoverlapping toxicity of both immune and targeted therapies (summarized later and reviewed in detail by Szczepaniak Sloane et al 104 in this issue of Cancer) have triggered interest in combining these therapies in the clinic.
Combined treatment with vemurafenib and adoptive lymphocyte transfer therapy in mouse tumor models showed better antitumor effects than either treatment alone. 105 Although some reports indicate that MEK inhibitors may inhibit T-cell function, BRAF inhibitors do not compromise T-cell activity but instead induce melanoma antigen expression, which may improve tumor recognition by T lymphocytes. 106 Treatment with a BRAF inhibitor alone or in combination with a MEK inhibitor is associated with increased CD8 1 T-cell infiltration, increased T-cell cytotoxicity, and decreased expression of immunosuppressive molecules such as interleukin 6 and interleukin 8; this further supports the potential of combining BRAF/MEK inhibitors with immunotherapy. 107, 108 Induction of PD-L1, an immunosuppressive ligand, is also associated with PI3K-mediated resistance to the BRAF inhibitor vemurafenib, 109 and PD-L1 upregulation in tumor cells that have acquired resistance to BRAF inhibition has been reported in several studies. 110, 111 Hence, concurrent inhibition of the MAPK pathway and immune checkpoint signaling may prove a potent antitumor combination therapy.
The combination of trametinib with immune checkpoint inhibitors targeting PD-1, PD-L1, or CTLA-4 was more effective than the use of each inhibitor alone in mouse tumor models. 110 Clinical trials combining MAPK inhibitors with immune checkpoint inhibitors are currently underway (NCT01940809, NCT02130466, and NCT02858921).
112,113

CONCLUSIONS
In conclusion, despite the novel approaches of combination treatments, resistance to combination therapies is rapid and common. Approximately 50% of melanoma patients treated with combined BRAF and MEK inhibitors (dabrafenib plus trametinib) acquire resistance and progress within 12 months, whereas patients treated with combined AKT and MEK inhibitors (afuresertib and trametinib) show a poor initial response. 103 Gene expression analysis revealed that MAPK reactivation was the predominant mechanism of resistance in
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BRAF/MEK inhibitor-treated resistant melanomas, although the profile of MAPK-reactivating mechanisms differed slightly in monotherapy versus combination MAPK inhibitor resistance. In particular, BRAF splice variants were common in BRAF inhibitor resistance; MEK2 mutations, rather than MEK1 mutations, were predominant in combination-resistant melanomas; and NRAS mutations were common in both monotherapy and combination MAPK inhibitor resistance. 100, 114 These data support models showing that combination therapies will fail if single mutations conferring crossresistance exist. 115 Thus, new treatment strategies may require triple or more complex drug combinations that target multiple independent pathways aside from the MAPK and PI3K/AKT pathways that do not share common resistance effectors, including immunotherapy.
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